Predicted Trait | |
Reported Trait | Prostate cancer |
Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
Score Construction | |
PGS Name | GRS72_PCa |
Development Method | |
Name | Variants associated with prostate cancer |
Parameters | NR |
Variants | |
Original Genome Build | NR |
Number of Variants | 72 |
Effect Weight Type | log(OR) |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000227 |
Citation (link to publication) | Xu J et al. Prostate (2021) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
Europe PMC: 19767752 |
[ ,
100.0 % Male samples |
European | ProtecT, UKGPCS |
— | [ ,
100.0 % Male samples |
European | 37 cohorts
|
GWAS Catalog: GCST001942 Europe PMC: 23535732 |
22,548 individuals | European | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
2,080 individuals | Hispanic or Latin American | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
6,954 individuals | East Asian | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
10,463 individuals | Sub-Saharan African, African American or Afro-Caribbean | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
67,543 individuals | European | NR |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
3,226 individuals | East Asian | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
2,251 individuals | African American or Afro-Caribbean | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
3,629 individuals | Hispanic or Latin American | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
37,272 individuals | European | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST000153 Europe PMC: 18264098 |
23,226 individuals | European | ICR, IGD, deCODE |
GWAS Catalog: GCST000489 Europe PMC: 19767754 |
37,350 individuals | European | ICR, IGD, deCODE |
GWAS Catalog: GCST006085 Europe PMC: 29892016 |
140,254 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM002522 | PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Number of positive prostate cancer tumour cores at diagnostic biposy | OR: 1.23 [1.06, 1.41] | — | — | Age at diagnosis, study site | — |
PPM002523 | PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Number of positive prostate cancer tumour cores at surveillance biposy | OR: 1.26 [1.11, 1.44] | — | — | Age at diagnosis, study site | — |
PPM002524 | PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Bilateral positive prostate cancer tumor cores at diagnostic biopsy | OR: 1.27 [1.01, 1.61] | — | — | Age at diagnosis, study site | — |
PPM002525 | PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Bilateral positive prostate cancer tumor cores at surveillance biopsy | OR: 1.19 [1.04, 1.36] | — | — | Age at diagnosis, study site | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS001140 | All individuals were prostate cancer cases undergoing active surveillance. Patients with favourable-risk prostate cancer and low-volume favourable intermediate-risk prostate cancer were enrolled. Favorable‐risk PCa was defined as Gleason grade group (GG) = 1 and prostate‐specific antigen (PSA) < 10 ng/ml. Low‐volume favorable intermediate‐risk in our study was defined as ≤2 positive cores, and only one of the following characteristics: GG ≤ 2 and/or PSA 10–20 ng/ml. At diagnostic biopsy 765 individuals had 1 tumour core, 272 had 2 tumour cores and 152 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at diagnostic biopsy, 1127 were unilateral and 95 were bilateral. At any surveillance biopsy 408 individuals had 1 tumour core, 297 had 2 tumour cores and 506 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at any surveillance biopsy, 635 were unilateral and 582 were bilateral. | — | 1,237 individuals, 100.0 % Male samples |
Mean = 65.16 years | European | — | JHH, NSUHS | — |